For decades, glioblastoma has defied medicine's best efforts, leaving most patients with little more than a year to live. Researchers at UCLA have now identified a protein called endocan — produced by the tumor's own blood vessels — as a hidden architect of that resistance, one that quietly signals cancer cells to withstand radiation and spread deeper into the brain. By interrupting this molecular conversation with an existing drug, scientists extended survival in preclinical models, offering not a cure, but something medicine has long needed: a clearer picture of how these tumors protect them
News-Medical.net
· Jan 08, 2025
· health
· 3 min read
High
Sourcing: Verified
UCLA Scientists Identify Endocan as New Target for Glioblastoma Treatment
Glioblastoma patients face dire prognosis with average 12-15 month survival and only 5% five-year survival rate, making new treatment approaches critical.
◉
Health & Medicine
8951 related articles
FDA Approves Pancreatic Cancer Drug That May Extend Patient Survival
CBS News · 100% match
Kerala oncologist outlines breast cancer warning signs and self-exam s…
Malayala Manorama · 99% match
US Aid Cuts Hamper Ebola Response in DRC, Aid Workers Say
CNN · 99% match
Viral Hantavirus Treatment Video Actually Shows COVID-19 Care from 202…
Tempo.co English · 99% match
Spanish health chief resigns after admitting he jumped vaccine queue
Reuters · 99% match
Related Coverage
BBC News · Sep 04
UK new-build crisis: defects, mould force families from homes as ombudsman complaints triple
Dozens of UK homebuyers report serious defects in new-build properties including mould, structural issues, and damp. Com…
The Guardian · Sep 04 New Zealand becomes second nation to approve MDMA for severe PTSD treatmentNew Zealand's Medsafe approved two psychiatrists to prescribe pharmaceutical-grade MDMA for severe PTSD, making it only …
Insurance Business · Sep 04 Intact Insurance Defeats Chronic Pain Claim Under Ontario's Minor Injury CapA Licence Appeal Tribunal rejected a claimant's attempt to exceed Ontario's $3,500 minor injury cap following a 2023 car…
News-Medical · Sep 04 Study identifies how prednisone impairs bone health in children with muscular dystrophyResearch identifies blood proteins explaining how prednisone, while treating Duchenne muscular dystrophy, impairs childh…
Bias & Framing
⚖
Science journalism article presenting UCLA research on glioblastoma treatment with straightforward reporting and minimal detectable bias.
Bias Direction
center
Confidence
HIGH
Standard medical research reporting using expert authority and clinical significance framing. Presents findings as promising advancement without overstating claims or inserting editorial perspective.
aggressive and lethal
imperative
lethal type of brain cancer
Patient or survivor perspectives on glioblastoma treatment
Potential limitations or skeptical expert commentary on the research
Timeline for clinical trials or practical application
Cost or accessibility considerations for future treatments
Competing research approaches from other institutions
Geopolitical Impact
🌎
UCLA scientists' discovery of endocan as a glioblastoma treatment target has no direct geopolitical implications; it is a medical research advancement with potential healthcare benefits.
Escalation Risk
low
Confidence
HIGH
Economic Lens
📈
UCLA discovery of endocan as glioblastoma treatment target could create new biotech opportunities and expand oncology drug development market, with potential for combination therapies.
Market Signal
bullish
Confidence
MED
Biotechnology/Pharmaceutical
Medical Devices
Healthcare Services
Cancer Research
Hospital/Clinical Services
Patients with glioblastoma may gain access to more effective treatment options that improve survival rates and quality of life; however, new therapies typically carry high costs that could increase healthcare expenses for patients and insurers.
FDA may expedite review pathways for endocan-targeting therapies given high unmet medical need; healthcare systems may need to allocate resources for clinical trials; insurance coverage policies may evolve to include combination radiation-immunotherapy approaches.